Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: A 24-week randomised, double blind exploratory study;Milnacipran et venlafaxine à posologie flexible (jusqu'à 200 mg/j) dans le traitement ambulatoire des épisodes dépressifs majeurs modérés à sévères de l'adulte : étude exploratoire de 24 semaines, randomisée en double insu

Encephale

Volumn 35, Issue 6, 2009, Pages 595-604

  Olie J P ^a   Gourion, D ^b   Montagne, A ^c   Rostin, M ^c   Poirier, M F ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b Pierre Fabre médicament ^*  (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Adult; Major depressive disorder; Milnacipran; Serotonin and norepinephrine reuptake inhibitors; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; CYCLOPROPANE DERIVATIVE; MILNACIPRAN; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; FRANCE; HUMAN; MAJOR DEPRESSION; MALE; MIDDLE AGED; MULTICENTER STUDY; PERSONALITY TEST; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SUICIDE;

ADULT; AGED; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; SEROTONIN UPTAKE INHIBITORS; SUICIDE; YOUNG ADULT;

EID: 77649092561     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2009.10.011     Document Type: Article

References (21)

1. Ansseau M., Von Frenckell R., Gérard M.A., et al. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine. Eur Neuropsychopharmacol 1 (1991) 113-121
2. Bauer M., Tharmanathan P., Volz H.P., et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 259 3 (2009) 172-185
3. Clauw D.J., Mease P., Palmer R.H., et al. Milnacipran treatment for fibromyalgia syndrome: one-year durability of response. Neurology 70 1-suppl (2008) A162 [abstract]
4. Deakin J.F.W. Does selectivity matter?. Int Clin Psychopharmacol 11 Suppl. 1 (1996) 13-17
5. Guy W. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology. Publication ADM No.76-338. Rockville, MD, USA: National Institute of Mental Health; 1976.
6. Guze S.B., and Robins E. Suicide and primary affective disorders. Br J Psychiatry 117 (1970) 437-438
7. Hayashi M., Mimura M., Otsubo T., et al. Effect of high-dose milnacipran in patients with depression. Neuropsychiatr Dis Treat 3 5 (2007) 699-702
8. Kasper S. Problèmes quotidiens du traitement de la dépression. CNS Spectr 13 7-suppl. 11 (2008) 4-5
9. Lecrubier Y, Sheehan D, et al. M.I.N.I. 5.0.0 French version/DSM-IV/current (August 1998).
10. Le Pape A, Lecomte T. Prévalence et prise en charge médicale de la dépression, France 1996-1997. Paris: CREDES; 1999.
11. Lépine J.P., Gastpar M., Mendlewicz J., et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1 (1997) 19-29
12. Machado M., Iskedjian M., Ruiz I., et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 22 9 (2006) 1825-1837
13. Mease P.J., Clauw D.J., Gendreau R.M., et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol 36 2 (2009) 1-12
14. Möller H.J., and Volz H.P. Drug treatment of depression in the 1990s: an overview of achievements and future possibilities. Drugs 52 (1996) 625-638
15. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 13 (1979) 382-389
16. Montgomery S.A., Baldwin D.S., Blier P., et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22 6 (2007) 323-329
17. Murray CJL, Lopez A. The Global Burden of Disease. In: The Global Burden of Disease and Injury Series (volume I). Boston, MA, USA: Harvard University Press; 1996.
18. Okumura K., and Furukawa T.A. Remission rates with milnacipran 100 mg/day and 150 mg/day in the long term treatment of major depression. Clin Drug Invest 26 3 (2006) 135-142
19. Stahl S.M., Grady M.M., Moret C., et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10 9 (2005) 732-747
20. Steen A., and Den Boer J.A. A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder. Int Clin Psychopharmacol 12 5 (1997) 269-281
21. Weissman M.M., Bland R.C., Canino G.J., et al. Cross national epidemiology of major depression and bipolar disorder. JAMA 27 (1996) 293-299